BB
GTHX

BB Biotech’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

BB Biotech’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$11.2M Hold
671,925
– – 0.28% 32
2018
Q4 		$12.9M Buy
671,925
+246,607
+58% +$9.24M 0.41% 33
2018
Q3 		$22.2M Buy
425,318
+72,711
+21% +$3.96M 0.59% 28
2018
Q2 		$15.3M Buy
+352,607
New +$15.1M 0.44% 29

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BB Biotech's GTHX Position: Q1 2019 in Review

BB Biotech held its G1 Therapeutics, Inc. Common Stock (GTHX) position steady in Q1 2019 at 671,925 shares worth $11.2M. The position accounts for 0.28% of the portfolio, ranked #32.

BB Biotech first reported a position in GTHX in Q2 2018 and has held it in 4 quarters since. The position peaked at $22.2M in Q3 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q1 2019.

  • BB Biotech held 671,925 shares of G1 Therapeutics, Inc. Common Stock worth $11.2M as of Q1 2019.
  • BB Biotech left its G1 Therapeutics, Inc. Common Stock share count unchanged in Q1 2019.
  • G1 Therapeutics, Inc. Common Stock made up 0.28% of BB Biotech's portfolio in Q1 2019, its #32 holding.
  • BB Biotech first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and has held it in 4 quarters since.
  • BB Biotech's G1 Therapeutics, Inc. Common Stock position peaked at $22.2M in Q3 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.